Product Information
PAXLOVID 300-100 MG DOSE PACK is a brand product labeled by Pfizer Inc., priced at $49.2398 per EA under NDC 00069532130. Its NADAC has been published 123 times since Jan 17, 2024.
FDA first approved this application on May 25, 2023.
Manufacturer
Pfizer Inc.NDC
00069532130
Classification
Brand
Dosage Form
KIT
Effective Date
5/20/2026
Approval Type
New Drug (NDA)
FDA Application
NDA217188FDA Approved
5/25/2023
On Market Since
10/18/2023
Price Statistics
The NADAC for PAXLOVID 300-100 MG DOSE PACK has been published 123 times since Jan 17, 2024, and over the history we have for it it has risen 10.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.2398 per EA |
|---|---|
| All-time high | $49.2992 (May 13, 2026) |
| All-time low | $44.5332 (Apr 17, 2024) |
| 52-week high | $49.2992 |
| 52-week low | $47.8414 |
| Median price | $47.8414 |
| Average price | $47.1909 |
| Largest weekly change | +4.5% (Jul 3, 2024) |
| Weeks tracked | 123 |
| Tracking since | Jan 17, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
-0.1%
1Y
+2.9%
3Y
N/A
5Y
N/A
All
+10.2%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
nirmatrelvir and ritonavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PAXLOVID 300-100 MG DOSE PACK?
The current National Average Drug Acquisition Cost (NADAC) for PAXLOVID 300-100 MG DOSE PACK, manufactured by Pfizer Inc., is $49.2398 per EA (NDC 00069532130), effective May 20, 2026.
How has the price of PAXLOVID 300-100 MG DOSE PACK changed over time?
Over the history we have for it, the NADAC for PAXLOVID 300-100 MG DOSE PACK has risen 10.2%. It has been tracked across 123 weekly CMS publications since Jan 17, 2024.
What are the highest and lowest recorded NADAC prices for PAXLOVID 300-100 MG DOSE PACK?
Since Jan 17, 2024, the NADAC for PAXLOVID 300-100 MG DOSE PACK has ranged from a low of $44.5332 (Apr 17, 2024) to a high of $49.2992 (May 13, 2026), with a median of $47.8414 per EA.
Are there cheaper alternatives to PAXLOVID 300-100 MG DOSE PACK?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PAXLOVID 300-100 MG DOSE PACK, is $49.2371 per EA — about 0% below PAXLOVID 300-100 MG DOSE PACK.
Who manufactures PAXLOVID 300-100 MG DOSE PACK?
PAXLOVID 300-100 MG DOSE PACK (NDC 00069532130) is labeled by Pfizer Inc., and CMS classifies it as a brand product.